Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Falls 9.6% Following Analyst Downgrade

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) dropped 9.6% during mid-day trading on Monday after JPMorgan Chase & Co. lowered their price target on the stock from $10.00 to $7.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. Recursion Pharmaceuticals traded as low as $2.89 and last traded at $2.8750. 12,297,236 shares were traded during trading, a decline of 37% from the average daily volume of 19,608,584 shares. The stock had previously closed at $3.18.

RXRX has been the subject of a number of other research reports. Morgan Stanley set a $5.90 price target on Recursion Pharmaceuticals in a research note on Friday, October 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Thursday, October 15th. Wall Street Zen raised Recursion Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 7th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $8.00 target price on shares of Recursion Pharmaceuticals in a research note on Monday, October 19th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Recursion Pharmaceuticals has an average rating of “Hold” and an average target price of $7.58.

Get Our Latest Research Report on RXRX

Insider Activity at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 40,000 shares of the business’s stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $3.88, for a total value of $155,200.00. Following the completion of the transaction, the director owned 6,068,287 shares of the company’s stock, valued at approximately $23,544,953.56. The trade was a 0.65% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Robert Hershberg sold 25,000 shares of the company’s stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $5.00, for a total transaction of $125,000.00. Following the transaction, the director owned 162,156 shares in the company, valued at $810,780. This represents a 13.36% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 167,408 shares of company stock valued at $701,276 over the last ninety days. Insiders own 6.65% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC bought a new stake in shares of Recursion Pharmaceuticals in the first quarter worth $7,370,000. Bank of New York Mellon Corp lifted its holdings in Recursion Pharmaceuticals by 29.3% in the first quarter. Bank of New York Mellon Corp now owns 1,462,631 shares of the company’s stock valued at $4,490,000 after acquiring an additional 331,048 shares during the period. Bank of America Corp DE lifted its holdings in Recursion Pharmaceuticals by 18.2% in the first quarter. Bank of America Corp DE now owns 2,496,831 shares of the company’s stock valued at $7,665,000 after acquiring an additional 384,486 shares during the period. First Trust Advisors LP boosted its position in Recursion Pharmaceuticals by 15.2% in the first quarter. First Trust Advisors LP now owns 2,610,726 shares of the company’s stock worth $8,015,000 after purchasing an additional 344,035 shares during the last quarter. Finally, California State Teachers Retirement System boosted its position in Recursion Pharmaceuticals by 64.0% in the first quarter. California State Teachers Retirement System now owns 574,637 shares of the company’s stock worth $1,764,000 after purchasing an additional 224,332 shares during the last quarter. Institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Trading Down 8.6%

The firm has a market capitalization of $1.81 billion, a P/E ratio of -3.23 and a beta of 1.15. The stock has a 50 day simple moving average of $3.78 and a 200-day simple moving average of $3.49.

Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last issued its quarterly earnings data on Monday, November 2nd. The company reported ($0.22) earnings per share for the quarter, hitting the consensus estimate of ($0.22). The firm had revenue of $18.55 million for the quarter, compared to analysts’ expectations of $14.81 million. Recursion Pharmaceuticals had a negative net margin of 697.15% and a negative return on equity of 47.85%. During the same quarter in the prior year, the business earned ($0.36) EPS. As a group, sell-side analysts expect that Recursion Pharmaceuticals, Inc. will post -0.89 earnings per share for the current fiscal year.

About Recursion Pharmaceuticals

(Get Free Report)

Recursion Pharmaceuticals, Inc. is a biotechnology company that uses automation, large-scale biological and chemical data, and machine learning to discover and develop medicines. Its platform, known as Recursion OS, is designed to identify relationships between biological processes and potential treatments. The company develops drug candidates for areas including rare diseases and oncology, and it also works with pharmaceutical partners on drug discovery and development. Its research combines laboratory experiments with computational analysis to evaluate potential therapeutic targets and compounds.

Read More

Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.